BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1270 related articles for article (PubMed ID: 10597118)

  • 1. Use of proton-pump inhibitors in complicated ulcer disease and upper gastrointestinal tract bleeding.
    Howden CW
    Am J Health Syst Pharm; 1999 Dec; 56(23 Suppl 4):S5-11. PubMed ID: 10597118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial.
    Lai KC; Lam SK; Chu KM; Hui WM; Kwok KF; Wong BC; Hu HC; Wong WM; Chan OO; Chan CK
    Aliment Pharmacol Ther; 2003 Oct; 18(8):829-36. PubMed ID: 14535877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lansoprazole: an update of its place in the management of acid-related disorders.
    Matheson AJ; Jarvis B
    Drugs; 2001; 61(12):1801-33. PubMed ID: 11693467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Helicobacter pylori and nonsteroidal anti-inflammatory drugs: interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications--future research needs.
    Graham DY
    Am J Med; 2001 Jan; 110(1A):58S-61S. PubMed ID: 11166000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of lansoprazole against peptic ulcers induced by non-steroidal anti-inflammatory drugs: endoscopic evaluation of ulcer healing.
    Matsukawa Y; Tomita Y; Nishinarita S; Horie T; Kato K; Arakawa Y; Ko K; Shimada H; Nakano M; Kitami Y; Kurosaka H
    J Int Med Res; 1997; 25(4):190-5. PubMed ID: 9283991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
    Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
    Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study).
    Treiber G; Wittig J; Ammon S; Walker S; van Doorn LJ; Klotz U
    Arch Intern Med; 2002 Jan; 162(2):153-60. PubMed ID: 11802748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers.
    Arkkila PE; Seppälä K; Kosunen TU; Sipponen P; Mäkinen J; Rautelin H; Färkkilä M
    Eur J Gastroenterol Hepatol; 2005 Jan; 17(1):93-101. PubMed ID: 15647648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment.
    Wheeldon TU; Hoang TT; Phung DC; Björkman A; Granström M; Sörberg M
    Aliment Pharmacol Ther; 2003 Jul; 18(1):93-100. PubMed ID: 12848630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses.
    Gremse DA
    Expert Opin Pharmacother; 2001 Oct; 2(10):1663-70. PubMed ID: 11825309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting Helicobacter pylori eradication using a seven-day triple therapy with a proton pump inhibitor, tinidazole and clarithromycin, in Brazilian patients with peptic ulcer.
    Silva FM; Zaterka S; Eisig JN; Chehter EZ; Chinzon D; Laudanna AA
    Rev Hosp Clin Fac Med Sao Paulo; 2001; 56(1):11-6. PubMed ID: 11378678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough?
    O'Connor HJ; McLoughlin R; Kelly S; Laundon J; Cunnane K
    Aliment Pharmacol Ther; 1998 Mar; 12(3):273-6. PubMed ID: 9570262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of lansoprazole in eradication of Helicobacter pylori.
    Katoh M; Asaka M; Kudoh M; Kagaya H; Katagiri M; Takeda H
    J Clin Gastroenterol; 1995; 20 Suppl 2():S112-4. PubMed ID: 7594324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin.
    Pilotto A; Franceschi M; Longoa MG; Scarcelli C; Orsitto G; Perri FC; D'Ambrosio LP; Leandro G
    Dig Liver Dis; 2004 Oct; 36(10):666-70. PubMed ID: 15506665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of lansoprazole on peptic ulcers.
    Ohashi T; Sakata J; Haraguchi Y; Eto T
    J Clin Gastroenterol; 1995; 20 Suppl 2():S83-5. PubMed ID: 7594350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy.
    Bianchi Porro G; Parente F; Imbesi V; Montrone F; Caruso I
    Gut; 1996 Jul; 39(1):22-6. PubMed ID: 8881802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients.
    Asaka M; Kato M; Sugiyama T; Satoh K; Kuwayama H; Fukuda Y; Fujioka T; Takemoto T; Kimura K; Shimoyama T; Shimizu K; Kobayashi S;
    J Gastroenterol; 2003; 38(4):339-47. PubMed ID: 12743773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic effects of lansoprazole on peptic ulcers in elderly patients.
    Murakami M; Saita H; Takahashi Y; Kusaka S; Asagoe K; Dekigai H; Matsumoto M; Seki M; Mizuno M; Maeda S
    J Clin Gastroenterol; 1995; 20 Suppl 2():S79-82. PubMed ID: 7594348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
    Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
    Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.